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Liquid vehiclea b s t r a c t
Liqui-Pellet is considered to be the next generation oral dosage form. It is highly commercially feasible
unlike its predecessor, liquisolid formulation. Liqui-Pellet uses Liqui-Mass system, allowing the formula-
tion to overcome some of the critical drawbacks in liquisolid technology, which persisted more than two
decades. These drawbacks include poor flowability, poor compressibility and inability for high dose with-
out product being too heavy and bulky for swallowing. The investigation is an extension of the previous
work on the Liqui-Pellet. In order to make this novel oral delivery system a commercial product, it is pru-
dent to further understand the parameters affecting its drug release rate. Two major parameters affecting
the dissolution rate that is investigated are water and liquid vehicle (Tween 80) contents. It is found out
that reducing water content (from 8.62 ml to 4.76 ml which is 1.9 ml/0.95 ml per 20 g of API and excip-
ients) and increasing Tween 80 concentration (from 28% w/w to 32 or 36% w/w) in naproxen Liqui-Pellet
results to an increase in drug release rate; however, there is a limit of how much water and Tween 80 can
be employed. Outside of this range limit, the formulation would fail to produce Liqui-Pellet due to
agglomeration. The range limit of granulation liquid and liquid vehicle content are dependent on one
another. In the successful formulation where Liqui-Pellets are formed, the excellent-good flow properties,
resistant to friability and narrow size distribution makes it ideal for commercial production. SEM of the
Liqui-Pellet shows a smooth surface which is ideal for coating. The solid state analysis via XRPD and DSC
indicated reduced crystallinity of the drug which is expected.
 2020 The Society of Powder Technology Japan. Published by Elsevier B.V. and The Society of Powder
Technology Japan. All rights reserved.1. Introduction
It is well known that there are many water insoluble drugs fac-
ing a critical drawback of poor bioavailability, either in the market
or in the development pipeline. The poor bioavailability is typically
due to poor drug dissolution rate. It is stated that around 60% of
drugs in the market and 40% of drugs in the development stage
are poorly water-soluble [1].
In brief, Liqui-Pellet could be considered the next generation
oral dosage form, stemming from liquisolid concept and pelletiza-
tion technologies [2,3]. It should be made clear that Liqui-Pellet is
different fomliquisolid pellet. Liquisolid pellet was first reported by
Pezzini et al. using the classical liquisolid system [4]. Liqui-Pellet isessentially different compared to liquisolid technology where the
former uses Liqui-Mass system instead of liquisolid system. This
essentially means that the mixture of active ingredient and excip-
ients is not essentially a free-flowing powder, but instead can be a
wet mass or paste. The formulation only becomes free-flowing
powder when the wet mass is transformed into the pellet form
using extruder/spheroniser. Due to this key difference, the new
dosage form is called Liqui-Pellet and not liquisolid pellet.
In studies by the authors, Liqui-Pellet has shown remarkable
potential for increasing drug release rate, whilst overcoming the
drawbacks of the classical liquisolid technology [2,3]. The key
drawbacks of the classical liquisolid formulation are poor flowabil-
ity, poor compressibility and incapable of producing high dose drug
in an acceptable size and weight [5,6]. Liqui-Pellet on the other
hand, can achieve excellent-good flow properties with high liquid
load factor without compromising the inherent advantages of liqui-
solid technology as shown in the authors previous studies [2,3].cal per-
2 M. Lam et al. / Advanced Powder Technology xxx (xxxx) xxxLiqui-Pellet has a range of inherent advantages, making it
uniquely different and desirable compared to other drug dissolu-
tion enhancing technologies. Unlike a lot of current technologies,
Liqui-Pellet can hold all three major advantages of being simple,
cost-effective and safer due to more predictable drug release and
absorption [5,6]. Additionally, it uses green technology and may
potentially resolve issues with polymorphism if API kept in a liquid
state. The incorporation of a high amount of liquid medication
whilst having the ability to achieve excellent flowability and the
potential for versatile modification makes Liqui-Pellet an exciting
and interesting dosage form. The high liquid load factor can poten-
tially make high dose Liqui-Pellet formulation without becoming
too bulky. It is in fact thought to be potentially highly commer-
cially feasible unlike its predecessor [2,3].
There are additional advantages in having the formulation in a
pellet form. Pellet form reduces the risk of dose dumping and small
uniform size of pellets allows a more predictable drug dispersion
and transportation in the gastrointestinal tract (GIT) [7]. The small
size of the pellet allows better distribution in the GIT, which could
improve bioavailability due to better drug absorption. Further-
more, since drug is freely distributed in the GIT, there is reduced
risk of high drug concentration at the local site; thus, risk of toxi-
city and side effects can be reduced [8]. Also, there is less variation
in gastric emptying; hence inter and intra variability of plasma
drug profile is minimized, reducing the risk of side effects [9,10].
Among the pelletization technique, extrusion-spheronization is
the chosen technique for this study. This is because it has a major
advantage in that it is capable of having high loading of API with-
out producing very large particles [11,12]. The API is integrated
within the pellet structure unlike some pelletization technique
where the API is only present at the surface of the pellet. In addi-
tion, the extrusion-spheronization technique can produce pellets
with uniform size, good flowability, narrow size distribution and
smooth surface [11].
Our previous study showed that naproxen Liqui-Pellet is able to
achieve excellent flow properties (in accordance to Carr’s com-
pressibility index and angle of repose) with a load factor of 1.52
(this is considered very high value) where 38% of total pellet mass
contains liquid vehicle [2,3]. Initially, in the early studies, naproxen
Liqui-Pellet has high liquid load factor and excellent flowability but
the drug release rate is slow (~17% release after 2 h at pH1.2) [2].
This is due to the use of microcrystalline cellulose (MCC) as a car-
rier. MCC-based pellet produced from extrusion-spheronization is
known to form a strong bond, which renders it virtually
non-disintegrating [13,14]. It is later found that this inability to
disintegrate is the drug release rate-limiting step in Liqui-Pellet
[2,3]. Modifications of the formulation are later carried out and it
is found that water content incorporated in extrusion-
spheronization is the key in determining Liqui-Pellet propensity
to disintegrate [3]. In addition, the amount of co-solvent used in
the formulation was observed to have an impact in disintegration
and drug release rate [2]; thus, it seems prudent to investigate the
water and co-solvent content parameters.
Water content is a crucial factor in a formulation containing
MCC; this is to achieve good rheological properties for a successful
pellet production via extrusion-spheronization [15]. Moisture con-
tent affects the internal porosity, friability, mechanical strength/-
cohesiveness, particle size distribution, shape and size of the
pellets [16,17]. In studies by Otsuka et al, an increase in water con-
tent results to increase hardness, which effectively reduces friabil-
ity due to the decrease of internal porosity of pellets [18]. Non-
volatile co-solvent such as Tween 80 has a plasticizing effect
[19], which can results in pellets with a better plastic property
because of the polymer transit from glassy to rubbery state [20].
In this study, the key objective is to observe the drug release
profile of Liqui-Pellet formulation made from varying water andPlease cite this article as: M. Lam, D. Commandeur, M. Maniruzzaman et al., Th
formance, Advanced Powder Technology, https://doi.org/10.1016/j.apt.2020.02co-solvent content. The study begins with investigating the most
suitable co-solvent among Tween 20, Tween 80 and Tween 85.
Afterwards, the water content will be varied in different formula-
tions to observe its effect on the drug release profile. Then the
specific effect of varying water and co-solvent content will be
investigated. With further understanding of the effect of drug
release of the mentioned parameters, it is possible to control and
tailor the dissolution behaviour of Liqui-Pellet.2. Materials and methods
2.1. Materials
Naproxen API was obtained from Tokyo Chemical Industry Co
(Japan). Other materials involved in the Liqui-Pellet production
included Avicel PH-101 (FMC corp., UK); Aerosil 300 (Evonik,
Germany); sodium starch glycolate Type A as superdisintegrant
(Primojel from DFE Pharma, Germany); polysorbate 20 liquid vehi-
cle (Tween 20), (Acros, Netherlands); polysorbate 80 liquid vehicle
(Tween 80), (Acros, Netherlands) and polysorbate 85 liquid vehicle
(Tween 85), (Acros, Netherlands). All other reagents and solvent
were of analytical grades.
2.2. Saturation solubility studies
Saturation solubility test of naproxen in 3 different non-volatile
co-solvents (Tween 20, Tween 80 and Tween 85) were carried out.
Only different types of Tween were used as previous studies
showed Tween 80 being the most suitable liquid vehicle among
polyethylene glycol 200, propylene glycol, Labrafil, Labrasol and
Kolliphor EL [2]. Excess naproxen powder was added into glass
vials containing 10 ml of liquid vehicle. The vials containing satu-
rated naproxen in a specified liquid vehicle were then placed in a
bath shaker (OLS Aqua Pro, Grant Instruments Ltd, UK). The sam-
ples were agitated under the shaking at a speed of 40 rpm for
72 h. Thereafter the sample’s supernatant was drawn out of the
vial using a syringe and then filtered through a pre-heated filter
(Millex syringe filter with pore size of 0.22 mm). The filtrated sam-
ple was then diluted with phosphate buffer solution (pH 7.4) fol-
lowed by determination of API using UV/vis spectrophotometer
analysis (Biochrom Ltd, UK) at a wavelength of 271 nm. Each test
was carried out in triplicates.
2.3. Preparation of naproxen Liqui-Pellet with different Tween
co-solvent
The preparation of Liqui-Pellet was made in a similar manner to
the authors’ previous studies [2,3]. The preparation includes
naproxen being mixed with a specified liquid vehicle (Tween 20,
Tween 80 and Tween 85) of specified amount via pestle and mor-
tar. All formulations in Table 1 had a ratio of carrier (Avicel PH-
101) to coating material (Aerosil 300) 20:1. Avicel PH-101 was
mixed into the liquid medication (naproxen and liquid vehicle)
where the carrier absorbs or adsorbs the liquid medication. The
mixture was transferred into a mixer (Caleva Multitab, Caleva Pro-
cess Solutions Ltd, UK) followed by the addition of primojel (super-
disintegrant) at a concentration around 5 %w/w. The mixer was set
at a constant rate of 125 rpm for 10 min with a specified amount of
granulating liquid (deionized water using SUEZ deionized water
system, France) added during the process. A specified amount of
Aerosil 300 was incorporated into the admixture, which under-
went an additional 10 min mixing. Thereafter the Liqui-Mass com-
position was extruded (125 rpm) and spheronized at 4000 rpm, but
may be adjusted between 2500 rpm and 4500 rpm to avoid
agglomeration or improve sphericity. Note that the duration ofe crucial effect of water and co-solvent on Liqui-Pellet pharmaceutical per-
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Table 1
Key formulation characteristics of the investigated Liqui-Pellet capsule.
Formulation Water content during extrusion-
spheronization (ml) per 20 g of


























6.01 – – – 58.15 2.90 Yes 90.58
LP-1 8.62 28 Tween
20
1 62.41 3.11 Yes 132.70
LP-2 8.62 28 Tween
80
1 62.41 3.11 Yes 132.70
LP-3 8.62 28 Tween
85
1 62.41 3.11 Yes 132.70
Note that all formulation contained 25 mg of naproxen, Primojel 5% w/w and the carrier to coating ratio of 20:1 respectively.
M. Lam et al. / Advanced Powder Technology xxx (xxxx) xxx 3spheronization process varied for each formulation, which was
dependent on factors such as extrudate plastic property, pellet
sphericity and risk of agglomeration. Next, the samples were dried
overnight using an oven (40 C). Details of each formulation com-
position are shown in Table 1.2.4. Preparation of naproxen Liqui-Pellet with varying water content
and co-solvent concentration
The Liqui-Pellet formulations in Table 2 were prepared in a sim-
ilar manner as the formulations in Table 1; however, the water
content and the amount of co-solvent added varied as shown in
Table 2. The ratio of carrier to coating material for all formulations
was 20:1. Note that not all formulations were successfully made as
agglomeration occurred during the spheronization process.Table 2
Key formulation characteristics of the investigate Liqui-Pellet capsule.
Formulation Water content during extrusion-
spheronization (ml) per 20 g of








LP-4 8.57 32 Tween
80
LP-5 8.57 36 Tween
80
LP-6 8.57 40 Tween
80
LP-7 8.57 44 Tween
80
LP-8 4.76 32 Tween
80
LP-9 4.76 36 Tween
80
LP-10 4.76 40 Tween
80
LP-11 4.76 44 Tween
80
LP-12 1.90 32 Tween
80
LP-13 1.90 36 Tween
80
LP-14 1.90 40 Tween
80
LP-15 1.90 44 Tween
80
LP-16 0.95 32 Tween
80
LP-17 0.95 36 Tween
80
LP-18 0.95 40 Tween
80
LP-19 0.95 44 Tween
80
Note that all formulation contained 25 mg of naproxen, Primojel ~5% w/w and the carri
Please cite this article as: M. Lam, D. Commandeur, M. Maniruzzaman et al., Th
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2.5.1. Flowability test on formulated Liqui-Pellet
Flow rate, angle of repose and Carr’s compressibility index were
determined for all formulations. This is done in the same manner
as in the authors’ previous work [1,2]. All successfull measure-
ments were done in triplicates. The following equations were used
to calculate the angle of repose and Carr’s Index:
Angle of repose
¼ tan1 height of heap of sample=radius of heap of the sampleð
ð1Þ
















1.18 57.57 3.88 Yes 132.70
1.38 52.77 2.64 No 132.70
1.63 47.96 2.40 No 132.70
1.94 43.16 2.16 No 132.70
1.18 57.57 3.88 Yes 132.70
1.38 52.77 2.64 Yes 132.70
1.63 47.96 2.40 No 132.70
1.94 43.16 2.16 No 132.70
1.18 57.57 3.88 Yes 132.70
1.38 52.77 2.64 Yes 132.70
1.63 47.96 2.40 No 132.70
1.94 43.16 2.16 No 132.70
1.18 57.57 3.88 Yes 132.70
1.38 52.77 2.64 No 132.70
1.63 47.96 2.40 No 132.70
1.94 43.16 2.16 No 132.70
er to coating ratio is 20:1 respectively.
e crucial effect of water and co-solvent on Liqui-Pellet pharmaceutical per-
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Table 3
Solubility of naproxen Liqui-Pellet in Tween 20, 80 and 85 at 37 C (n = 3).
Non-volatile
solvent
Mean concentration (mg/ml) ± SDa Inference
Tween 20 17.98 ± 3.09 Sparingly
soluble
Tween 80 21.85 ± 1.88 Sparingly
soluble
Tween 85 14.27 ± 1.58 Sparingly
soluble
a SD, standard deviation from the mean
4 M. Lam et al. / Advanced Powder Technology xxx (xxxx) xxxwhere qb being the poured density and qt being the tapped density.
2.5.2. Friability test on formulated Liqui-Pellet
The method of friability test was the same as the authors’ pre-
vious friability studies [2,3]. This method adapted a similar method
that was used in Hu studies [21], with additional modification such
as sealing the friabilator to prevent pellets from leaving the con-
tainer. Specified sample of Liqui-Pellets weighing 3 g in total and
glass beads also weighing 3 g in total were placed in a friabilator
(D-63150, Erweka, Germany). The friabilator was set to 100 rota-
tions in 4 min). The percentage weight loss of the formulation
was determined by means of the weight of the pellets prior to
and after the friability test.
2.5.3. Particle size analysis via sieve method
The distribution of particle size was determined using sieves
method (Test sieve, Retsch, Germany). All formulations that were
successfully extruded and spheronized were tested. Specified sam-
ple of Liqui-Pellet (5 g) was sieved via a mechanical shaker (AS 200,
Retsch, Germany), which was set at an amplitude of 60 for a min-
ute then the amplitude of 40 for 9 min. Sieve size used were 2000,
1000, 850, 500, 250 mm. The Liqui-Pellet yield in percentage was
then determined.
2.5.4. Scanning electron microscope (SEM) analysis
The surface morphology of the Liqui-Pellet formulations was
studied using SEM (Jeol JMS 820, Freising, Germany). Each sample
was placed in double-sided carbon tape and sputter-coated with
gold using a sputter coater with gold target and Argon gas under
5 kV for 5 min. Once coated the samples were placed into the
SEM machine (operating at 3 kV) where the surface structure
was investigated at magnifications of 80 and 800.
2.6. In-vitro dissolution test
The dissolution tests were carried out in a similar manner as in
the authors’ previous publication on naproxen Liqui-Pellet [2,3].
USP paddle method (708-DS Dissolution Apparatus & Cary 60
UV–Vis, Agilent Technologies, USA) was the chosen dissolution test
method. The dissolution medium used were either 900 ml of HCl
buffer solution (pH of 1.2) or 900 ml phosphate buffer solution
(pH of 7.4). The temperature was set at 37.3 ± 0.5 C and paddle
agitation at 50 rpm. Absorbance was set at 271 nm and samples
were taken at different time intervals of 5 min until 1 h then time
interval of 10 min for another hour.
Dosage of 25 mg of naproxen was used for all dissolution tests,
mainly because naproxen has poor solubility profile under acidic
environment (i.e. pH 1.2). This is due to naproxen weak acidic
properties, where it is well known that acidic APIs are usually
insoluble in an acidic environment but soluble in a basic environ-
ment. According to studies by Mora and Martinez [22], naproxen
solubility at 35 C and pH 1.2 was 1.16  104 mol/L or 27 mg/L;
hence, 25 mg were chosen as a reasonable amount of drug for this
test. For convenience, 25 mg of naproxen were also used at pH 7.4.
Although at pH 1.2, the sink condition was not maintained, the key
purpose was to compare the various formulations.
2.7. Differential scanning calorimetry (DSC) and X-ray powder
diffraction (XRPD) studies
DSC and XRPD were performed on excipients, naproxen and all
successful formulations to assess their crystallinity. For DSC (DCS
4000, Perkin Elmer, USA), between 3 and 6 mg of sample were
weighed and sealed in an aluminium pan. The thermal behaviour,
which correlates to the crystallinity, was investigated at a scanning
rate of 10 C/min, from 25 C to 200 C under nitrogen atmosphere.Please cite this article as: M. Lam, D. Commandeur, M. Maniruzzaman et al., Th
formance, Advanced Powder Technology, https://doi.org/10.1016/j.apt.2020.02X-ray diffractometer (D5000, Siemens, Germany) was used to
analyze the samples with scanning angle ranged from 5 to 40
with a scan rate of 0.02/s. Voltage and current were set to 40 kV
and 30 mA respectively. The relative crystallinity of the sample
was determined using the integrated peak method (Eq. (3)) and
peak height method (Eq. (4)) [23]. For integrated peak method,
the area under the curve was calculated using the trapezoid
method.
% XRD relative crystallinity ¼ As=Arð Þ  100 ð3Þ
% XRD relative crystallinity ¼ Hs=Hrð Þ  100 ð4Þ2.8. Mathematical analysis
Data from the dissolution studies were mathematically ana-
lyzed using difference factor (f1) equation Eq. (5) and similarity fac-
tor (f2) equation Eq. (6) as described by Moore and Flanner [24].
The US FDA (Food and drug administration) recommended these
mathematical analyses for comparing dissolution profiles recom-
mended [25], which have been included in various guidance docu-
ments issued by the FDA [26,27]. Difference factor with a value
between 0 and 15 and similarity factor with a value between 50
and 100 indicates equivalence of the two dissolution profiles
[28]. Details of the equations can be found in various literature
[25,29–31]; however, in general, n represents the number of disso-
lution sample times and Rt & Tt represent the mean % of drug dis-










f2 ¼ 50  log 1þ 1=nð Þ
Xn
t¼1






; ð6Þ3. Results and discussion
3.1. Saturation solubility studies
Results from the saturation solubility study (Table 3) shows
naproxen is sparingly soluble in Tween 20, Tween 80 and Tween
85. Among the mentioned Tween liquid vehicles, which are non-
ionic surfactant derived from sorbitan ester [32], naproxen has
the highest solubility in Tween 80 (21.85 mg/ml) and least soluble
in Tween 85 (14.27 mg/ml). This agrees with data from the disso-
lution studies where Tween 80 has the highest drug release rate
and Tween 85 is the slowest. T-test was performed to compare
the significance of the solubility data and the results showed that
although Tween 80 showed the highest solubility the difference
in the solubility between Tween 80 and Tween 20 was not signif-
icant (p > 0.05), but the difference was significant when comparede crucial effect of water and co-solvent on Liqui-Pellet pharmaceutical per-
.025
Table 5
Weight loss of 3 g of each formulation under
rotational speed of 25 rpm for 4 min.
Formulation % Weight loss










M. Lam et al. / Advanced Powder Technology xxx (xxxx) xxx 5to the solubility of naproxen in Tween 85 (p > 0.05). The general
assumption is that the formulation containing the liquid vehicle
that the API is most soluble in, would have the fastest drug release
rate. The increase in the dissolution rate could be as a result of
increasing the surface area of API in the formulation due to the
presence of solubilised form or molecularly dispersed form of API
[33].
The differences in the solubility in various Tweens are due to
their different properties; however, the detailed explanation
remains unclear. On comparing the HLB (hydrophilic-lipophilic
balance), Tween 20 (HLB = 16.7) have the highest HLB followed
by Tween 80 (HLB = 15.0) then Tween 85 (HLB = 11.0) [34]; how-
ever, these HLB value does not seem to show a clear correlation
with the solubility data or results from the drug release rate. This
reinstates how predicting solubility is complex and require consid-
eration of additional factors such as viscosity, polarity, chemical
structure and molecular mass may affect drug release [6].
3.2. Success of spheronizing formulation
Not all formulations were successfully spheronized into pellets.
Tables 1 and 2 show which formulations were successful and
which failed in producing pellets. In general, there seems to be a
limit of how much water and the liquid vehicle can be added until
the formulation is prone to agglomeration, leading to failure in
Liqui-Pellet production.
Within the spectrum of water content used in this investigation,
8.62 ml of water (per 20 g of API and excipients admixture) is con-
sidered high water content. At this water content, only the lowest
spectrum of co-solvent (32% w/w) was able to successfully produce
Liqui-Pellet. By increasing the co-solvent above 32% w/w with this
high water content formulation, the extrudates produced, have
cohesive surface and highly plastic properties, which lead to
agglomeration during the spheronization process. It seems like
there is a synergistic effect of water and Tween 80 in enhancing
extrudate plastic properties. The non-ionic surfactant Tween 80
has a plasticizing effect [19] contributing to the rheology of the
wet mass and extrudates. Care must be taken into consideration
so that the extrudates are plastic enough to form spherical pellets
when spheronized but not to the extent that would result in
agglomeration.
At the mid spectrum of water content (4.76 ml and 1.9 ml of
water per 20 g of API and excipients admixture), it is possible to
make Liqui-Pellet with higher Tween 80 content (36% w/w). TheTable 4









10.72 ± 0.33 19.96 ± 1.43 11.11 ± 0.62 Excellent fl
LP-1 8.77 ± 0.16 23.81 ± 0.74 10.08 ± 0.55 Excellent fl
LP-2 8.22 ± 0.29 23.51 ± 0.19 12.11 ± 0.64 Excellent fl
LP-3 8.08 ± 0.07 23.95 ± 0.21 12.73 ± 0.00 Excellent fl
LP-4 6.74 ± 0.08 28.7 ± 0.20 11.05 ± 1.36 Excellent fl
LP-8 7.17 ± 0.10 27.63 ± 0.31 10.17 ± 0.63 Excellent fl
LP-9 7.07 ± 0.11 27.65 ± 1.00 6.31 ± 0.70 Excellent fl
LP-12 6.12 ± 0.18 31.02 ± 0.66 7.33 ± 0.00 Good flow
LP-13 6.4 ± 0.19 29.52 ± 0.85 3.96 ± 0.00 Excellent fl
LP-16 5.57 ± 0.25 30.87 ± 0.55 5.80 ± 0.74 Excellent-g
a For the composition of each formulation refer to Table 1 and Table 2.
b SD, standard deviation from the mean.
Please cite this article as: M. Lam, D. Commandeur, M. Maniruzzaman et al., Th
formance, Advanced Powder Technology, https://doi.org/10.1016/j.apt.2020.02reason for this is because the water content is reduced, thus, the
overall plasticity and cohesiveness of the extrudates do not go over
the limit that can cause agglomeration. At this mid-range of water
content, Tween 80 above 36% w/w, all agglomerated during
spheronization process. Despite some of the extrudates appearing
ideal for pellet production (i.e. short and brittle enough to break),
the increased in the liquid vehicle made the extrudates’ surface
too cohesive that agglomeration could not be avoided.
Similar to the high spectrum of water content, the lowest spec-
trum of water content (0.95 ml of water per 20 g of API and excip-
ients admixture), could only produce Liqui-Pellet successfully at
low liquid vehicle concentration (32% w/w). The lack of water in
the formulation affects the rheological properties of the extrudate
in such that concentration of Tween 80 at 36% w/w and higher,
were too soft and cohesive to be spheronized into pellets. Overall,
it can clearly be seen that understanding the water and liquid vehi-
cle limits in the formulation process is prudent for the success of
producing Liqui-Pellet.3.3. Flow properties
All successfully made formulations have shown excellent,
excellent-good or good flowability (Table 4). The data from the
authors’ previous work also show similar results, indicating clearly
that Liqui-Pellet can overcome its predecessor’s (liquisolid technol-
ogy) drawback of poor flow property [2,3]. This is a major step for-
ward in bringing a concept from liquisolid technology towards a
commercial direction.n = 3).
ccording to Angle of Inference according
to CI%












owability Good flowability 70.75 28.09 1.16
owability Good flowability 86.28 12.50 1.22
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PMP LP-1 LP-2 LP-3 LP-4
LP-8 LP-9 LP-12 LP-13 LP-16
Fig. 1. SEM images of physical mixture pellet and all successful formulation under 80 magnification and 800 magnification.
Fig. 2. Dissolution profile of 25 mg of naproxen Liqui-Pellet in capsule with different liquid vehicle (Tween 20, Tween 80 and Tween 85) and physical mixture pellet at pH 1.2.
6 M. Lam et al. / Advanced Powder Technology xxx (xxxx) xxxThe consistently used Tween 80 in this investigation is classi-
fied as a surfactant according to ‘Handbook of Pharmaceutical
Excipients’ [32]. A surfactant that has high HLB value tends to
reduce sharkskin effect on the extrudates, which is the result of
decreased frictional force at the die wall of extrusion screen. This
helps to produce pellets with higher sphericity [34]. The highPlease cite this article as: M. Lam, D. Commandeur, M. Maniruzzaman et al., Th
formance, Advanced Powder Technology, https://doi.org/10.1016/j.apt.2020.02degree of sphericity contributes to the desired flow property that
is evident in Table 4.
It is noteworthy to mention that some of the formulations have
a liquid load factor as high as 1.38, where the total mass of pellet
contains a considerable amount of liquid medication of 55%. Fur-


































Fig. 3. Dissolution profile of 25 mg of naproxen Liqui-Pellets in capsule with different water and liquid vehicle content under pH 1.2.
M. Lam et al. / Advanced Powder Technology xxx (xxxx) xxx 7a major issue in Liqui-Pellet, the production is simplified by not
having to rely on the liquisolid mathematical model that was intro-
duced by Spireas.
3.4. Friability test
All of the successfully produced formulations have a weight loss
of less than 1% (Table 5), which is the limit of weight loss considered
acceptable for tablet according to the USP. Liqui-Pellet formulations
fromtheauthors’previous studiesalsohaveaweight lossof less than
1% [2,3]. Presently there is no standard for friability test for pellets;
however, it seems reasonable to say that the current Liqui-Pellet
dosage form is robust enough in regards to commercial standard.
These Liqui-Pellets contain MCC as a carrier, which has strong
bonding within its structure when water is added; in addition,
the Tween 80 gives the formulation its plastic properties. Both of
these enhance Liqui-Pellet resistant to friability, which is sup-
ported by the data presented in Table 5.
3.5. Particle size of formulated Liqui-Pellet via sieve method
Results obtained from the particle size analysis (Table 4), clearly
shows narrow size distribution of all of the formulations apart
from physical mixture pellet. Physical mixture pellets have rela-
tively wider size distribution than the rest of the formulations
(54% within 1 mm and 45.21% within 0.85 mm). This could be
due to the absent of Tween 80 during physical mixture pellet pro-
duction. Without Tween 80 the wet mass and extrudates would
have less plastic properties, which could results in poorer pellet
quality with wider size distribution.
The formulations that have exceptionally narrow size distribu-
tion are LP-4 (around 99% within 0.5 to 0.85 mm), LP-8 (around 95
within 0.5 to 0.85 mm), LP-9 and LP-12 (around 99% within 0.5 to
0.85 mm), LP-13 and LP-16 (around 98% within 0.5 to 0.85 mm)
(Table 4). These narrow size distributions are ideal for commercial
manufacturing, particularly when considering the uniformity of
drug content during the filling process into capsules.
It is interesting how the changes in water content and Tween 80
concentration did not have a significant influence on thePlease cite this article as: M. Lam, D. Commandeur, M. Maniruzzaman et al., Th
formance, Advanced Powder Technology, https://doi.org/10.1016/j.apt.2020.02Liqui-Pellet size distribution. The formulation containing 8.62 ml
of water per 20 g of Liqui-Mass admixture (LP-4) and 0.95 ml of
water per 20 g of Liqui-Mass admixture (LP-16) showed 99%
and 98% within 0.5 to 0.85 mm respectively. It seems like the
Tween 80 could be contributing to the reduced variability in plastic
properties, consequently reducing the variability of size distribu-
tion among the formulation.
It should be noted that there are many parameters that can
affect the pellet size produced from extrusion-spheronization. In
brief, these key parameters include moisture content [16,17]; type
and amount of granulating liquid [18]; spheronization speed, load
and duration; and drying method [35]. Thus, it is actually rather
difficult to be certain if parameters such as the amount of water
or liquid vehicle are actually influencing the pellet size. Nonethe-
less, it is clear that it is possible to produce Liqui-Pellet with nar-
row size distribution and within the size that would allow it to
have short transit time in the stomach (<2 mm).3.5.1. Studies of surface structure via SEM
There is a clear difference in the surface structure of Liqui-Pellet
formulations and physical mixture pellet (Fig. 1). The surface of all
of the Liqui-Pellet formulations has smooth round pebble-like
appearance, which is not present in the physical mixture pellet
(PMP). Among the different type of Tween co-solvents, Tween 20
(LP-1) shows the smallest bump size on the surface, which could
suggest that the type of Tween may influence surface morphology.
The rest of the formulations’ surface structure looks similar to one
another, with the exception of variations in bump size. It appears
that LP-16 has slightly larger bumps, which protrude more than
the rest of the formulations. It should be noted that the priority
focus of the study is to see if it is possible to produce Liqui-Pellet
with different amount of water and Tween 80 content; thus, in
order to achieve this, the spheronization duration and speed were
varied for optimal success rate. This may have an impact on the
surface structure of the Liqui-Pellet formulations.
It is interesting to point out that in the previous study, the for-
mulation that contained 29% w/w Tween 80 did not have the

































Fig. 4. Dissolution profile of 25 mg of naproxen Liqui-Pellets in capsule with different water and liquid vehicle content under pH 7.4.
Fig. 5. Diffraction peaks of naproxen, avicel, aerosil, primojel, physical mixture pellet and all of the successful formulations.
8 M. Lam et al. / Advanced Powder Technology xxx (xxxx) xxxseems to appear when the amount of Tween 80 is increased from
29% to 32% or 36% in this study.
All of the Liqui-Pellet formulations have a relatively smooth
surface structure which is an important factor for successful coat-
ing [11]. The coating of these pellets is an important considerationPlease cite this article as: M. Lam, D. Commandeur, M. Maniruzzaman et al., Th
formance, Advanced Powder Technology, https://doi.org/10.1016/j.apt.2020.02when making sustained and controlled release Liqui-Pellet formu-
lation via polymeric coating. In addition, smooth surface and
spherical shape of the Liqui-Pellet would make it easier to apply
taste masking polymer [36–39], which may have benefits in the
pediatric formulation.e crucial effect of water and co-solvent on Liqui-Pellet pharmaceutical per-
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Table 6
Relative crystallinity in respect to AUC at 18.9 peak among physical mixture pellet,
LP-4, LP-8, LP-9, LP-12, LP-13 and LP-16.
Formulation % relative crystallinity via
integrated peak area method
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Fig. 2 shows that the type of liquid vehicle used in the prepara-
tion of formulations has an impact on the dissolution rate of API
where formulation containing Tween 80 showed faster drug disso-
lution compared to other liquid vehicles used (Fig. 2). The results
correspond well to the saturation solubility studies (Table 3) in
which naproxen is most soluble in Tween 80 and least soluble in
Tween 85.
Results from Fig. 3 show the dissolution profile of all successful
formulations under acidic pH of 1.2, which mimics the pH in the
stomach. The figure clearly shows that the amount of water con-
tent and liquid vehicle concentration have a crucial effect on the
drug dissolution profile of Liqui-Pellet. In general, a reduction in
water content used in the preparation of Liquid-Pellets increases
drug release rate (compare LP-4, LP-8, LP-12 and LP-16), and an
increase in Tween 80 concentration increases drug release rate
(compare LP-12 and LP-13).
Using mathematical analysis, it is possible to some degree to
confirm that decreasing water content has an impact on the drug
release rate. Formulation LP-8 (4.76 ml of water per 20 g of
Liqui-Mass admixture) has an increase of 4% of drug release after
2 h compared to LP-4 (8.62 ml of water per 20 g of Liqui-Mass
admixture) with f1 = 14.54 and f2 = 79.07. Even though the f1
and f2 value does not show a significant difference, as the water
content further decreases, it is possible to see the influences of
water content on dissolution rate (Fig. 3). For example, when the
water content is further decreased from 8.62 ml of water per
20 g of Liqui-Mass admixture (LP-4) to 1.9 ml of water per 20 g
of Liqui-Mass admixture (LP-12), the drug release rate increased
by 13% after 2 h with f1 = 33.87. This f1 value shows that the dis-
solution rate of both of these formulations are different; LP-12
drug release rate is faster than LP-4. Furthermore, when the water
content is again further decreased from 8.62 ml of water per 20 g of
Liqui-Mass admixture (LP-4) to 0.95 ml of water per 20 g of Liqui-
Mass admixture (LP-16), the drug release rate increased by 16%
with f1 = 39.22 and f2 = 50.34. It is clear that f1 value is increasing
and f2 value is decreasing with decreasing water content, indicat-
ing that the drug release rate is becoming more different with
changes in water content. The f1 of 39.22 signifies the difference
in drug dissolution rate of LP-16 and LP-4. It should be pointed
out that the f1 value seems to show differences in dissolution pro-
file but not the f2 value. It is worth stating that there seems to be no
well-defined basis for the equivalence threshold of f2 = 50 [25].
The enhanced drug release rate with decreased water content in
the formulation can be explained in terms of MCC aggregates sub-
unit. Sarkar and Liew state that MCC is made up of aggregates of
small subunits, which are held together via hydrogen bond [40].
In order for de-aggregation of MCC subunit to occur, these hydro-
gen bond must be broken [40]. By taking Sarkar and Liew state-
ment into account, when less amount of water content is used
during the mixing stage, there is less polar granulating liquid to
cause de-aggregation. This would lead to MCC with larger particle
size. During granulation and extrusion process of this larger MCC
particle size, along with less moistening liquid content, results to
less surface tension and van der Waals forces; the wet mass and
extrudate have reduced cohesive strength. Essentially this would
produce pellets with weaker cohesive strength; thus, better
propensity for disintegration, which results to faster drug release
rate as disintegration is the drug release rate-limiting step for
MCC-based Liqui-Pellet [2,3].
The effect of liquid vehicle content can be seen in formulation
LP-12 (32% w/w Tween 80) and LP-13 (36% w/w Tween 80).
Despite both having the same water content of 1.9 ml per 20 g of
Liqui-Mass admixture, the difference of 12% dissolution rate after
2 h is due to the different concentration of Tween 80. The f1 = 36.75Please cite this article as: M. Lam, D. Commandeur, M. Maniruzzaman et al., Th
formance, Advanced Powder Technology, https://doi.org/10.1016/j.apt.2020.02indicates that LP-12 and LP-13 have a different dissolution rate; LP-
13 having faster drug release rate than LP-12. Hence, Tween 80
content in the formulation does influence the drug release rate.
However, the significant f1 and f2 values are not seen for LP-8
(32% w/w Tween 80) and LP-9 (36% w/w Tween 80) where
4.76 ml of water per 20 g of Liqui-Mass admixture is used
(f1 = 7.64 and f2 = 87.94). It seems that Tween 80 has a greater
impact on drug dissolution rate when the water content is respec-
tively lower.
The increase in drug release rate with increasing liquid vehicle
is due to more API being solubilized or in a molecularly dispersed
state, which results in an increase in surface area available for dis-
solution [33]. This can also be explained using the Noyes-Whitney
equation, where the surface area available for dissolution is
directly proportional to dissolution rate [41]. In addition to the
increased surface area available for dissolution, Tween 80 reduces
surface tension or cohesive force, which improves propensity for
disintegration; thus, further enhancing drug release rate. A similar
finding in terms of Tween 80 improving disintegration of MCC-
based pellet was observed by Chamsai and Sriamornsak [14].
When comparing formulation LP-4 with LP-13, the combined
effect of decreased water content and increased Tween 80 shows
a significant increase in drug release by 25% after 2 h with
f1 = 51.56 and f2 = 40.10. In summary, water and Tween 80 (or liq-
uid vehicle) are crucial parameters influencing drug release rate of
Liqui-Pellet. Reduced water content and increased Tween 80
improves the drug release rate of Liqui-Pellet. At the lower spec-
trum of water content, Tween 80 have a more prominent effect
on drug release rate than at higher spectrum of water content.
Nonetheless, there are limits of how much water can be reduced
and how much Tween 80 can be increased. Table 2 shows which
formulations failed to form Liqui-Pellets at particular water con-
tent and Tween 80 concentration, indicating the limits.
Dissolution studies at pH 7.4 (Fig. 4) show a fast drug release
rate of all successfully made Liqui-Pellet formulations, which pla-
teau at 20 min. This fast drug release rate is expected because
naproxen is a weakly acidic drug, which is more soluble in alkaline
pH than acidic pH environment.
3.7. XRPD studies
The diffractogram in Fig. 5 shows that naproxen peak at 2h val-
ues of 6.4, 12.28, 12.96, 16.32, 18.72, 19.88, 22.16, 23.40, 26.96 and
28.04, which is very similar to the naproxen peak from previous
studies [2,3]. The peak in physical mixture only corresponds to
naproxen and Avicel, indicating that there is no interaction
between API and the excipients. The physical mixture looks less
crystalline than pure naproxen as the crystallinity of naproxen
can be covered by the amorphousness of microcrystalline cellulose
and/or excipients i.e. aerosil and primojel used in the formulation.
As XRPD of all Liquid-Pellets formulations is similar to the XRPD
of the physical mixture pellet, the authors made an attempt to usee crucial effect of water and co-solvent on Liqui-Pellet pharmaceutical per-
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Fig. 6. DSC thermograms of naproxen.
Fig. 7. DSC thermograms of excipients (aerosil, avicel PH101 and primojel).
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Fig. 8. DSC thermograms of physical mixture and all successful formulation.
M. Lam et al. / Advanced Powder Technology xxx (xxxx) xxx 11sharp peaks (area and height) to estimate the crystallinity of each
formulation. The relative crystallinity measured is with respect to
AUC at 18.9 peak (Table 6). Note that the data does not represent
the whole percentage of crystallinity of each formulation as only
one crystalline peak is used for the analysis. The purpose of this
study is to observe if the API crystallinity differs among each other;
thus, using the AUC at 18.9 peak seems sufficient for the task. The
results from the integrated peak area method show that all the
Liqui-Pellet formulations (LP-4, LP-8, LP-9, LP-12, LP-13 and LP-
16) have a slight reduction in the crystallinity in comparison to
physical mixture pellet. This is expected as API are solubilized or
held in a molecularly dispersed state in Liqui-Pellet formulation;
hence, the crystallinity of API is reduced as indicated in the results.
This reduction in the crystallinity of Liqui-Pellet formulations is
not very remarkable as the concentration of drug in the formula-
tions is very low compared to the other components of the formu-
lation. The results from peak height method also show similar
trend except for formulation LP-12, where it seems to be slightlyPlease cite this article as: M. Lam, D. Commandeur, M. Maniruzzaman et al., Th
formance, Advanced Powder Technology, https://doi.org/10.1016/j.apt.2020.02more crystalline than the physical mixture pellet. It should be
noted that there are quite a fewmethods of measuring crystallinity
via XRPD. This reflects the intricacy in obtaining accurate results.3.8. DSC studies
The naproxen crystalline state is presented as a sharp endother-
mic peak (Tm = 160.45 C and DH = 64.23 J/g), which is shown in
Fig. 6. Thermograms of excipients are shown in Fig. 7; they display
broad peaks for Avicel (Tm = 76.36 C and DH = 80.73 J/g) and Pri-
mojel (Tm = 79.76 C and DH = 257.79 J/g), which could be due to
water evaporation within these hygroscopic excipients. Similar
observations are seen from the authors’ previous publications [2]
and in Tiong and Elkordy work [42]. In contrast, Aerosil has not
revealed any thermal transition at the heating range (25–200 C)
because of its amorphous nature and the Tg value being higher
than the experimented range.e crucial effect of water and co-solvent on Liqui-Pellet pharmaceutical per-
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12 M. Lam et al. / Advanced Powder Technology xxx (xxxx) xxxIn comparing the naproxen and physical mixture pellet thermo-
grams (Fig. 6 and Fig. 8), there is a slight shift of peak from
160.45 C to 154.50 C, respectively. This is likely caused by the
influence of Avicel affecting the overall peak of naproxen in the
physical mixture pellets. As temperature increases, API dissolves
in the excipients, shifting the peak towards the left. Nonetheless,
the crystalline state of naproxen is still present in the physical mix-
ture pellet. This peak that indicates a crystalline state of naproxen
becomes less prominent in the rest of the successful Liqui-Pellet
formulations, implying that the Liqui-Pellet formulations crys-
tallinity is reduced. This reduced crystallinity is due to the pres-
ence of naproxen in solubilized or molecularly dispersed state,
which is supported by the enhanced drug dissolution rate of
Liqui-Pellet formulations compared to physical mixture pellet.
4. Conclusion
Liqui-Pellet is a new and exciting technology; however, it is still
in its infancy. The investigation of the amount of water and Tween
80 as parameters in Liqui-Pellet formulation clearly show that they
have a crucial effect on the drug release profile. It can be seen that
the combined effect of decreased water content and increased
Tween 80 can significantly increase drug release rate i.e. by
25% (referring to LP-3 and LP-4 after 2 h). The reduction of water
enhances drug release by reducing the cohesive strength of the
Liqui-Pellet, which improves its disintegrating properties. The
increase in Tween 80 concentration enhances drug release through
increasing the proportion of drug being in solubilized or molecu-
larly dispersed state. This increases the surface available for disso-
lution. In addition, Tween 80 reduces surface tension or cohesive
force, which improves propensity for disintegration, contributing
to the enhanced drug release rate. Despite reducing water and
increasing Tween 80 contents resulting in faster drug release rate,
there is a limit of how much water can be reduced and how much
Tween 80 can be increased. Outside of this limit, the Liqui-Pellet
formulation is likely to fail due to agglomeration. The fact that
Liqui-Pellet drug release rate can be tailored by adjusting the men-
tioned parameters whilst maintaining excellent flow properties
with a narrow size distribution. This is an indication of the flexibil-
ity in the formulation design of Liqui-Pellte which makes it a very
valuable oral drug delivery system.
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